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Summary
Objective: The purpose of this work was to test the effect of inhibition of bone remodeling, through the use of the bisphosphonate, zoledronic
acid, on cartilage matrix damage in an animal model of cartilage matrix damage.
Design: New Zealand white rabbits were divided into four groups for treatment purposes: (1) untreated controls; (2) injected into one knee
joint with the cartilage matrix degradation enzyme, chymopapain; (3) injected into one knee joint with chymopapain and also given
subcutaneous injections of the bisphosphonate, zoledronic acid, three times per week until sacrifice at either day 28 or 56 post-
chymopapain-injection; (4) received only the zoledronic acid injections. At sacrifice, the knee joints were examined grossly and histologically,
and biochemically for proteoglycan content. Urine samples were analysed, at intervals, for levels of collagen cross-links which are
biochemical markers of cartilage and bone.
Results: Animals receiving both intraarticular chymopapain injections and subcutaneous zoledronic acid injections displayed a significantly
lower degree of grossly and histologically detectable cartilage degeneration on the tibial articular surfaces (the articular surface displaying
the greatest degree of degeneration) than did animals only receiving the chymopapain injections. In addition, urinary levels of collagen
cross-links for bone and cartilage were significantly higher in those animals only receiving chymopapain injections.
Conclusion: The bone resorption observed after chymopapain injection into the rabbit knee joint can be inhibited through the use of the
bisphosphonate, zoledronic acid. Furthermore, zoledronic acid does not increase the level of cartilage degeneration and appears to provide
some level of chondroprotection in this model. © 2002 OsteoArthritis Research Society International
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Osteoarthritis (OA) is a debilitating condition that is charac-
terized by irregularly distributed focal loss of articular
cartilage1 in connection with a reaction in the subchondral
bone. However, the exact relationship between the carti-
laginous and bony changes has yet to be elucidated.
An association between bone and cartilage changes has
been demonstrated in studies showing an increased bone
mass in osteoarthritic patients2–12, an association between
thickened subchondral bone and OA13, and an inverse
relationship between OA and osteoporosis14.
Radin et al.15–18 proposed that denser and stiffer
subchondral bone is less capable of absorbing and dis-
tributing forces at the joint and, thus, transmits greater force
to the overlying articular cartilage. The cartilage, not being
able to withstand these increased forces becomes
damaged. In addition, inhomogeneities in the subchondral226bone thickness and/or stiffness created by remodeling may
result in a differential deformation of the overlying cartilage
contributing to its degradation19 with associated anabolic
and catabolic responses from the chondrocytes. Certainly
the remodeling of subchondral bone in relation to the pro-
gression of cartilage degeneration should be considered.
Previously, Uebelhart et al.20 demonstrated that the
intraarticular injection of chymopapain resulted in cartilage
matrix damage with accompanying bone changes. In this
model of cartilage damage, the urine levels of deoxypyri-
dinoline (D-Pyr), a specific marker of bone resorption21,22
and pyridinoline (Pyr), a less specific marker of metabolic
changes in bone, increased dramatically within the first few
days after chymopapain injection, possibly indicating bone
resorption. In the present study we have utilized this
cartilage damage model to test the hypothesis that the
inhibition of bone remodeling, through the use of the
bisphosphonate zoledronic acid, affects cartilage integrity.Materials and methods
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Fifty-eight adolescent male New Zealand white rabbits
(4.0 kg in weight) were assigned to one of four groups: (1)
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LEVELS OF AGKS
Blood was obtained by venipuncture on each of the two
days prior to, on the day of (but prior to chymopapain
injection), 24 and 48 h after chymopapain injection and
once per week thereafter. Blood samples were allowed to
clot at 4°C, centrifuged, after which the serum was obtained
and analysed for content of antigenic keratan sulfate
(agKS) to ensure that degradation of articular cartilage PG
occurred in all animals injected with chymopapain.
AgKS was measured by a modified enzyme-linked
immunosorbent assay as previously described25,26. All
determinations were done in duplicate. Values are reported
as equivalents of the International Standard of agKS puri-
fied from human costal cartilage (a gift from Drs M. B.
Mathews and A. L. Horwitz, University of Chicago, IL,
U.S.A.).COLLECTION OF URINE SAMPLES AND MEASUREMENT OF PYR
AND D-PYR
Twenty-four-hour urine samples were collected from the
individual animal’s metabolic cages every day at the sametime (early afternoon), including during the acclimation
period. Samples were centrifuged and frozen at −20°C
until analysed for pyridinium cross-links and, in some
cases, for creatinine determination. Urine samples from
days −1, 0, 1, 2, and 7 (where day 0 is the day of, but prior
to the time of, chymopapain injection) and every 7 days
until sacrifice thereafter were subjected to cross-link deter-
mination. Urinary creatinine determination was measured
for three animals as a test for normal urinary output. No
correction for creatinine was subsequently made in the
groups as the ratio of creatinine to D-Pyr did not change
over time in the three animals studied. This confirmed a
previous finding that levels of urinary creatinine content did
not affect the urinary levels of Pyr and D-Pyr in rabbits20.
Urinary levels of D-Pyr are reported as the absolute values
in pmol/ml.
Measurements of Pyr and D-Pyr cross-links of collagen
were made through an HPLC assay of urine hydrolysates
as previously described20.TISSUE COLLECTION AND GRADING
At sacrifice, femoral, tibial and patellar articular surfaces
were examined and graded blindly on a five-point gross
visual scale27. Briefly, Grade 0=no signs of cartilage dam-
age; Grade 1=early fibrillation, shallow pits or grooves
affecting the cartilage surface in the absence of changes in
articular surface geometry; Grade 2=deep fibrillation and
fissuring or pitting and possibly small osteophytes; Grade
3=extensive fibrillation and fissuring and 30% or less of the
articular cartilage surface eroded down to the subchondral
bone and, generally, the presence of osteophytes; and
Grade 4=greater than 30% of the articular surface eroded
down to the subchondral bone and, generally, the presence
of prominent osteophytes. All cartilaginous and bony com-
ponents were examined for deviations from the normal
gross morphology as determined by comparison with those
of normal, untreated control animals as well as with the
uninjected contralateral knee.HISTOLOGICAL PREPARATION
Whole patellae from both knee joints were fixed in 10%
neutral buffered formalin, decalcified in aqueous formic
acid/sodium citrate (50:50), paraffin embedded, sectioned
to 6 m thickness and stained with Safranin O and fast
green28. Cartilage degeneration on these sections was
graded blindly on a 20-point scale for articular surface
integrity, Safranin O staining, clone formation and cellularity
as previously described20.
For subsequent morphometric analysis, whole tibias
from both knee joints were fixed in 10% neutral buffered
formalin, embedded in methylmethacrylate, sectioned to
6 m and stained with von Kossa tetrachrome29. Cartilage
degeneration on these sections was graded blindly on a
15-point scale for articular surface integrity, clone formation
and cellularity. This scale is the same as that for the
patellae which were stained with Safranin O except for the
absence of information on proteoglycan (PG).MEASUREMENT OF PG CONTENT
Full-thickness articular cartilage pieces, of approximately
2 mg, from the medial condyles of the femurs were papain
digested and analysed for PG content (per dry weight)untreated control (N=6 and 8 at 28-day and 56-day-
sacrifice respectively); (2) chymopapain injury without
zoledronic acid treatment (N=6 and 8 at 28-day and
56-day-sacrifice post chymopapain injection respectively);
(3) chymopapain injury with zoledronic acid treatment (N=8
and 8); (4) zoledronic acid treatment without chymopapain
injury (N=6 and 8).
Chymopapain (Chymodiactin, a gift of Boots Pharma-
ceuticals) injury in the left knee joint was carried out by
intraarticular injection of a sterile solution of 2.0 mg of the
enzyme activated by sodium L-cysteinate hydrochloride in
0.3 ml sterile saline. The control right knee of all animals
and both knees of the control animals were not injected
with saline as it has been previously reported that intra-
articular injection of sterile saline or water does not result
in subsequent detectable damage or changes in the joint
tissues23,24. The intraarticular injection of 2.0 mg of chymo-
papain was chosen because it was previously shown by
Uebelhart et al.23 that this dosage of chymopapain causes
a marked loss of proteoglycans (PGs), elevation of urinary
D-Pyr and irreparable articular cartilage lesions in maxi-
mally loaded regions of the injected joint. The right knee
was not injected in any of the animal groups, thus, serving
as a contralateral control.
The bisphosphonate, zoledronic acid, was used as the
bone remodeling inhibitor. It is a heterocyclic derivative of
pamidronate and is characterized by an imidazol ring and
extremely high activity (Novartis Pharma Compound Infor-
mation Sheet). Zoledronic acid (a gift of Novartis Pharma)
was administered by subcutaneous injection at a dose of
10 g/kg body weight three times per week. The zoledronic
acid injections began 24 h prior to the intraarticular injection
of chymopapain. The site of injection was varied within the
back region so as not to create cutaneous irritation.
All animals underwent a 5-day acclimation period
prior to any treatment. Animal weights were recorded
weekly throughout. The treatment protocol was approved
by the Institutional Animal Care and Use Committee of
Rush-Presbyterian-St. Luke’s Medical Center. Animals
were sacrificed at either 28 days (N=26) or 56 days
(N=32) after the intraarticular chymopapain injection (or
comparable time if no chymopapain was administered).
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methylene blue as previously described30.STATISTICAL ANALYSIS
Differences between the 28-day and 56-day sacrifice
groups at all time points measured and in all parameters
investigated were evaluated by the Wilcoxon signed rank
test and Students t-test where applicable. In addition, a two
way ANOVA was used to test both the effect of group and
the effect of duration of experimentation between the 28-
and 56-day groups. Once the data from the animals of the
two sacrifice groups was combined, the Kruskal–Wallis
Test was used to determine significant differences in
gross visual scores and histological scores between the
four animal groups. The individual groups were further
compared to each other using the Mann–Whitney Test.
The Wilcoxon signed rank test was used to compare the
articular cartilage scores of the chymopapain-injected
knees to the contralateral uninjected control knees.
Because the D-Pyr cross-link data were nonnormally
distributed, the non-parametric Friedman test was used
separately for each group to compare the D-Pyr cross-link
values at each time point. The non-parametric Kruskal–
Wallis and Mann–Whitney tests were carried out to com-
pare the study groups with respect to the differences
between the D-Pyr cross-link values at post-injections days
and the values at day 0.
The Student–Newman–Kuels test was used to assess
the proteoglycan values and KS values among the groups.
Differences in body weights among the treatment groups
were evaluated by the Kruskal–Wallis Test for each time
point described. Data are reported as the mean of each
treatment group±standard error of the mean. Statistical
significance was taken at P<0.05, but exact values are
given.ResultsEFFECT OF LENGTH OF STUDY
Animals experienced normal weight gain and there were
no significant differences in animal weight gains among any
of the four treatment groups (data not shown). The mean
weight gain was 0.41±0.04 kg for animals sacrificed
28 days after chymopapain injection and 0.57±0.05 kg for
animals sacrificed 56 days after chymopapain injection.
Because no significant differences in any of the parameters
measured (besides weight gain) were detected at individual
time points for animals sacrificed 28 days and those
sacrificed 56 days post-chymopapain-injection, the data
from these two groups are reported together.KS LEVELS
Pre-injection serum levels of agKS among the four
groups were: untreated control: 66.1±13.2 ng/ml; chymo-
papain injected: 74.4±9.2 ng/ml; zoledronic acid treated:
78.6±7.4 ng/ml; chymopapain/zoledronic acid: 78.7±
9.4 ng/ml. For each animal, the change in the serum level
of agKS at different time points was calculated by deduct-
ing the pre-injection baseline level from each post-injection
level. The pre- and post-injection serum levels for the
animals not receiving chymopapain injections werecalculated from the same time points as for the chymo-
papain injected animals. Serum agKS levels from all
animals receiving chymopapain injection increased sharply
compared to baseline values prior to injection thereby
substantiating cartilage matrix degradation (P<0.001)26.
This increase occurred in every animal receiving a chymo-
papain injection. The mean increase 24 h after injection as
compared to the pre-injection baseline was 214.8 ng/ml
(±32.8) for the chymopapain-injected group and 211.8 ng/
ml (±18.7) for the chymopapain/zoledronic acid treated
group (not a significant difference between the two groups).
AgKS values returned to pre-chymopapain injection values
within 48 h (data not shown). Serum agKS levels from
time-matched control animals (i.e. untreated and
zoledronic acid-treated only) that did not receive chymo-
papain injection did not change significantly at any time.PYR AND D-PYR LEVELS
Absolute urinary levels of D-Pyr rose significantly after
intraarticular chymopapain injection only in animals that
received chymopapain injections without zoledronic acid
treatment. These levels were significantly higher than pre-
injection values on days one, two, seven, fourteen and
twenty-one post-injection (P≤0.05; Fig. 1), after which time
the levels decreased to pre-injection values or lower and
remained there until sacrifice. The levels of D-Pyr did
not rise after chymopapain injection in any other group,
including the chymopapain/zoledronic acid treated group.
Furthermore, there were significant differences between
the chymopapain injected group and the other three treat-
ment groups with respect to the differences between the
D-Pyr cross-link values at post-injections days 2, 7, 14, and
21 as compared to the values at day 0 (P≤0.005).
The urinary Pyr levels mimicked those of the D-Pyr with
ratios between the two markers remaining fairly constant
throughout the study (data not shown).GROSS MORPHOLOGY
At sacrifice, all knee joints were opened and examined
for gross morphological degeneration to the articular carti-
lage, inflammation and osteophytosis. Osteophytes were
not seen in any knee joint from any of the four groups.
None of the uninjected right knee joints and none of the
untreated control or zoledronic acid-only animals displayed
gross evidence of cartilage degeneration on any articular
surface. No gross changes were observed on the femoral
or patellar articular surfaces of any animal in any of the four
groups. The tibial articular surface was the only surface that
displayed a grade greater than 1. Both chymopapain and
chymopapain/zoledronic acid treated animals showed
cartilage degeneration in the injected knee compared to the
control right knee (P<0.001). A comparison of the grades of
degeneration for the tibial surfaces of the left (treated) knee
joints can be seen in Fig. 2. Using the Kruskal–Wallis Test,
significant differences were found between the four animal
groups. Using the subsequent Mann–Whitney Test, the
gross visual grade of cartilage degeneration on the tibia
was significantly greater between the control and
zoledronic acid-only groups compared individually to the
chymopapain and chymopapain/zoledronic acid groups
(P<0.001). Furthermore, the gross visual grade in the
chymopapain animals was significantly greater than that of
the chymopapain/zoledronic acid animals (P=0.005).
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cartilaginous or bony components of the knee joints
between limbs within an animal or among the animal
treatment groups. In other words, we did not observe a
clubbing of the epiphyses or any other deviations from
the normal shape of the bone or articular surfaces, with the
exception of the cartilage surface degeneration in the
chymopapain injected animals.MICROSCOPIC APPEARANCE
Microscopic inspection of Safranin O stained sections
revealed that the articular cartilage of all control patellae
(no injection, from all treatment groups) had a smooth
surface, normal cellularity and intense staining for PGs
[Fig. 3(a)]. The patellar cartilage of all chymopapain-
injected knees (in animals both with and without zoledronic
acid injections) displayed varying degrees of surface fibril-
lation, cell loss, cell cloning and pronounced loss of
Safranin O staining [Fig. 3(b),(c)]. There was no significant
difference between the chymopapain and chymopapain/
zoledronic acid treated animals in cartilage histology
scores for the patellae of chymopapain-injected knees,however, a trend was noted (P=0.07) for less severe
damage in the chymopapain/zoledronic acid group
(Table I). A direct comparison in histological scores
between tibial and patellar articular surfaces can be seen in
the first two rows of Table I which report the sum of data
for surface disruption, cell loss and cell cloning. The
bottom row of Table I reports the data for patellar surfaces
including the Safranin O staining.
Microscopic inspection of von Kossa tetrachrome
stained tibial plateau articular surfaces revealed that the
articular cartilage of all control tibias (no injection, from all
treatment groups) had a smooth surface and normal cellu-
larity [Fig. 4(a)]. No information could be gleaned from
these sections concerning PG content since the von Kossa
tetrachrome stain was used, rather than Safranin O, to
distinguish between mineralized bone matrix and osteoid
for future bone morphometrics studies. The tibial cartilage
of all chymopapain-injected knees (of both chymopapain
and chymopapain/zoledronic acid treated animals) dis-
played surface disruptions, cell loss and cell cloning
[Fig. 4(b),(c)]. However, there was a significant difference
between the chymopapain and chymopapain-zoledronic
acid animals in cartilage histology scores for the tibial
articular cartilage of the chymopapain-injected knees
(P=0.001; Table I). No difference was noted between
the uninjected knees of the same groups, with all tibial
cartilages displaying a normal appearance.0
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Fig. 1. Urinary excretion of deoxypyridinoline (D-Pyr) at various times pre- and post-chymopapain (CP) injection for the four study groups.
The levels of D-Pyr were significantly higher (*) on days 2, 7, 14 and 21 post-CP injection as compared to levels prior to chymopapain
injection on day 0 for the chymopapain-injected group only (P≤0.05). Results are reported as the mean±S.E. Data are not available for day
56 of the untreated controls. Untreated controls ( ), N=6 at 28-day sacrifice and 8 at 56-day sacrifice; chymopapain-injected ( ), N=6 and
8; chymopapain injected/zoledronic acid treated ( ), N=8 and 8; zoledronic acid ( ), N=6 and 8.0
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Fig. 2. Gross visual scores of articular cartilage on tibial plateaus at
sacrifice (for 28-day and 56-day sacrifice groups). Results are
reported as the mean±S.E. A grade of 0 represents an articular
surface with no visible degeneration. There was a significant
difference between the scores of both the chymopapain-injected
(CP) and chymopapain-injected/zoledronic acid-treated (CP/Z)
groups and the control groups (P<0.001) and between the CP and
CP/Z groups themselves (P=0.005). UC=untreated controls;
Z=zoledronic acid.CARTILAGE PG CONTENT
As depicted in Fig. 5 the PG content in the articular
cartilage is expressed as the percentage of PG content in
the left knee (injected knee) as compared to the PG content
in the contralateral control knee at sacrifice. There were no
significant differences between both uninjected knees of
animals from untreated and zoledronic acid-only groups.
However, the reduced percentage of PG in the chymo-
papain and chymopapain/zoledronic acid animals con-
firmed that the intraarticular injection of chymopapain
resulted in a significant reduction in the PG content. PG
content was significantly lower in the chymopapain-injected
left knees (27% for chymopapain and 21% for
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uninjected right knees (P=0.001). Although there was
no significant difference between chymopapain and
chymopapain/zoledronic acid groups, there was a trend for
the chymopapain/zoledronic acid group to have a lesser
reduction in PG content (P=0.12).Fig. 3. Safranin O-stained sections of patellar articular surfaces. (a) Representative section from the patella of an uninjected knee joint. There
is an intact articular surface, normal cellularity, and intense staining for proteoglycan. (b) Representative sections from a chymopapain-
injected knee joint of an animal not receiving subcutaneous zoledronic acid injections and (c) from a chymopapain-injected knee from an
animal receiving zoledronic acid injections. Note the disrupted surface [as in (b)], reduced cellularity, clones [arrows in (b) and (c)] and loss
of staining (×100).Fig. 4. Von Kossa-stained sections of tibial plateau articular surfaces. (a) Representative section from the tibia of an uninjected knee joint.
There is an intact articular surface and normal cellularity. (b) Representative section from a chymopapain-injected knee joint of an animal not
receiving subcutaneous zoledronic acid injections. Note the severe disruption of the surface, the reduced cellularity and the presence of
clones (arrows). (c) Representative section from the chymopapain-injected knee of an animal receiving subcutaneous zoledronic acid
injections. Although surface disruptions, reduced cellularity and the presence of clones (arrows) were present, the degree of degeneration
was not as severe as in those animals not receiving zoledronic acid injections (×100).Discussion
The present study has established that the bone resorp-
tion observed after chymopapain injection into the rabbit
knee joint can be inhibited through the use of the bisphos-
phonate, zoledronic acid. The objective of the study was to
Osteoarthritis and Cartilage Vol. 10, No. 3 231Table I
Histologic scores for patellar and tibial articular surfaces at sacrifice. Because tibias were prepared for future bone morphometrics and
stained with Von Kossa tetrachrome (which provides no information on proteoglycan staining) the first two rows provide the mean scores for
surface integrity, clone formation and cellularity only. The scale was 0–15 with 15 representing the highest level of degenerative changes.
The third row of data presents the scores for patellar surfaces with the inclusion of the Safranin O staining scores along with the other three
histological parameters measured. In all three rows, significant differences were noted between untreated control and zoledronic acid-only
groups as compared to the chymopapain only and chymopapain/zoledronic acid groups (P<0.001). For the tibias, there was a significant
difference between the chymopapain group as compared to the chymopapain/zoledronic acid group
Treatment group: Mean histologic scores for patellar and tibial articular surfaces
Untreated
controls (n=14)
Chymopapain
(n=14)
Chymopapain/
zoledronic acid (n=16)
Zoledronic
acid (n=14)
Tibias 4±0 8.6±0.9* 5.8±0.5* 4±0
Patellae 3±0 7.3±0.5† 6.5±0.4† 3±0
Patellae (including Safranin O data) 4±0 10.5±0.6† 9.2±0.6† 4±0
(*P=0.001). For the patellae, there was no significant difference between the chymopapain group as compared to the chymopapain/
zoledronic acid group, but there was a trend for less severe damage in the chymopapain/zoledronic acid group (†P=0.07).0
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Fig. 5. Ratios of the proteoglycan content of the CP-injected knee
to the contralateral uninjected knee. Results are reported as the
mean±S.E. Both the chymopapain-injected (CP) and chymopapain-
injected/zoledronic acid-treated (CP/Z) groups were significantly
lower than the untreated control (UC) and zoledronic acid (Z)
groups (P=0.001). Although there was no significant difference
between the CP and CP/Z groups, there was a trend for the
CP/Z group to have closer PG levels between the injected and
uninjected contralateral knee.test the hypothesis that the inhibition of bone remodeling,
through the use of zoledronic acid affects cartilage integrity
after chymopapain injection. The chymopapain model was
used because it was previously shown to involve both bone
in addition to the well known cartilage changes as demon-
strated by an increase in the urinary levels of both cartilage
(Pyr) and bone (D-Pyr and Pyr) metabolic markers20. In the
present study, zoledronic acid reduced the urinary levels of
the bone-specific collagen cross-link marker, D-Pyr, after
chymopapain injection and did not alter the molar ratio of
Pyr/D-Pyr, thus suggesting that the most probable source
of Pyr and D-Pyr was bone. More importantly, this decrease
in bone resorption, along with a continued inhibition of bone
remodeling lessened the degree of degeneration of the
overlying cartilage on, at least, the most severely affected
articular surface of the knee joint, the tibial plateau.
The consistent drop in the urinary D-Pyr levels during the
study (and after 21 days post-chymopapain injection in
the chymopapain animals not receiving zoledronic acid) is
a finding consistent in growing animals and represents a
reduction in bone turnover as the animal ages20.
We deduced that the chymopapain and chymopapain/
zoledronic acid groups had approximately the same level of
cartilage degradation immediately following chymopapain
injection into the knee joint since the levels of agKS were
not significantly different between these groups. Saxneet al.31 previously demonstrated that circulating levels of
agKS correlated well with the concentration of aggrecan
core protein-related epitopes in serum, thus indicating that
the serum level of agKS is representative of the level of
aggrecan-derived fragments.
Because there were no significant differences in body
weight or gross tibial architecture between animal groups,
our results could not be due to differences in weight gain or
gross morphology of the rabbit knee joint.
We found no detectable differences in the degree of
grossly or histologically visible cartilage degeneration
between the 28-day sacrifice and 56-day sacrifice animals
within each group. It is possible that this period of time
is not long enough to detect measurable differences in
cartilage degradation or attempted repair.
Although no significant difference was found in the PG
content (as assessed from the cartilage of the medial
condyle of the femur) of the chymopapain and
chymopapain/zoledronic acid groups, treatment with
zoledronic acid showed a trend toward reduction in PG loss
in the chymopapain-injected knee. This was also the case
for the histological scores on the patellar cartilage. One
may speculate that since the cartilage damage was of a
lesser degree on this surface as compared to the tibia,
perhaps the damage was at an earlier stage, prior to the
development of discernible differences. It is possible that
these early changes may subsequently lead to the partial
chondroprotection observed in the later stages of cartilage
damage seen on the tibia. Thus, we may speculate that
the tibia is the only articular surface that degenerated to
the extent that a visual determination of zoledronic
acid-induced chondroprotection could be detected.
There are conflicting reports on the utility of bisphospho-
nates for the modulation of cartilage degradation in arthritis.
Long-term treatment of SRT/ORT mice with ethane-1-
hydroxy-1,1-disphosphonate (EHDP) failed to have an
effect on the incidence and severity of the naturally
occurring OA of their knee joints32. In another study, two
other bisphosphonates were found to have no effect on
collagen arthritis in rats33. Conversely, clodronate34 and
clodronate-containing liposomes35 were shown to
decrease the severity of adjuvant-induced arthritis in rats.
More recently, Podworny et al.23 showed that zoledronic
acid had a partial chondroprotective effect in the
carrageenan-induced model of inflammatory arthritis in the
rabbit knee joint as evidenced by a 30% reduction in the
total histological grading scores as compared to the non-
zoledronic acid treated, carrageenan-injected animals. In
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probably not in the reduction of inflammation since the drug
did not have an effect on the synovitis. Rather, the authors
cited the ability of zoledronic acid to maintain the integrity,
thickness and, to a lesser extent, the hardness of the
subchondral bone.
A different approach involving bone in the development
of OA can be found in a study by Manicourt et al.36
demonstrating that calcitonin treatment after anterior cruci-
ate transection in dogs inhibits the extent of cartilage
lesions. They reported that calcitonin treatment inhibited
the hypermetabolic changes associated with the develop-
ment of OA in this model, including the enhanced rate of
bone turnover.
There is also evidence that cancellous bone from
osteoarthritic femoral heads is metabolically more active as
compared with normal bone, particularly in the sub-
chondral region37. The authors showed that bone collagen
metabolism and the degradative potential (as demon-
strated by increased matrix metalloproteinase 2 activity) of
osteoarthritic bone was considerably higher37.
Although the mechanism of action of the intraarticular
injection of chymopapain on bone is not known, there was
a partial reversal of this action by zoledronic acid in the
present study. Bisphosphonates, as synthetic analogs of
the naturally occurring inhibitor of bone resorption, pyro-
phosphate, work by inhibiting the action of osteoclasts in
bone resorption38. Within this study we may only speculate
as to the relationship between the reduction in bone turn-
over markers and the partial chondroprotective effect
observed. The most likely explanation is that, similarly to
Podworny et al.’s study23, zoledronic acid was able to
inhibit bone turnover thereby maintaining the integrity of the
subchondral bone. Alternatively, a chymopapain-induced
breakdown of bony matrix that generates the release of
anabolic and/or catabolic factors may be lessened due
to the reduction in bone turnover during zoledronic acid
treatment.
It may be hypothesized that any bone turnover that takes
place subsequent to the chymopapain injection, as evi-
denced through the increase in collagen cross-links derived
from bone, changes the normal pattern of density or
stiffness of the bone and, thus, stress distribution across
the joint surface. It is this altered stress distribution that
may contribute to the damage observed on the overlying
cartilage18. By reducing remodeling and, therefore, the
altered stress distribution through the action of zoledronic
acid, a reduction in cartilage degeneration may thus ensue.
The bone remodeling inhibition by zoledronic acid may
also have a direct effect on the articular cartilage by
modulating the release of mediators from bone at a local
level. In support of this are the findings of Westacott
et al.39,40 that cartilage explants cultured in the presence
of bone-derived cells from osteoarthritic patients had a
significant increase in the release of glycosaminoglycan as
compared to those cultured with non-arthritic bone cells.
Finally, we must at least consider the possibility that
zoledronic acid exerts an effect directly on cartilage.
Although bisphosphonates have a highly selective localiz-
ation in bone, studies have shown that certain bisphospho-
nates can bind to41, and have a direct effect on cartilage.
For example, clodronate has been shown to stimulate both
bone and cartilage net collagen synthesis in vitro and
in vivo in growing rats42. Another study showed that SR
41319 and, to a lesser extent, EHDP inhibited the produc-
tion collagenase and neutral proteoglycan-degrading pro-teinases by MCF-stimulated chondrocytes and synovial
cells43.
In summary, the inhibition of bone remodeling by the
bisphosphonate, zoledronic acid, does not increase the
level of cartilage degeneration in this model of cartilage
matrix damage and appears to provide some level of
disease modification. Our results support the view that OA
is a disease of the whole joint and not merely a failure of the
cartilaginous component.Acknowledgments
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